Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Philip Morris International Inc. (NYSE:PM) resulting from allegations that Philip Morris may have issued materially misleading business information to the investing public. On December 20, 2017, Reuters published a report stating that "[f]ormer employees and contractors [of Phillip Morris] have detailed irregularities in the clinical experiments that underpin Philip Morris International's application to the FDA for approval of its iQOS smoking device." The report further stated that "Tamara Koval, who worked at the company from 2012 to 2014 and helped coordinate clinical trials for the device, questioned the quality of some of the researchers and sites contracted to carry out those experiments." The report added that "after [Koval] raised concerns about the Polish study with Philip Morris executives in Switzerland she was excluded from meetings." On this news, shares of Philip Morris fell sharply during intraday trading on December 20, 2017. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Philip Morris investors. If you purchased shares of Philip Morris, please visit the firm's website at http://www.rosenlegal.com/cases-1259.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.